EC approval of trastuzumab biosimilar Herwenda

Biosimilars/News | Posted 23/01/2024 post-comment0 Post your comment

The European Commission (EC) granted marketing authorization for trastuzumab biosimilar Herwenda on 15 November 2023. The biosimilar of Herwenda is developed by EirGenix, Inc.

Cancer image015

Trastuzumab is a monoclonal antibody that binds to and inactivates the HER2/neu receptor. In some cancers, notably certain types of breast cancers, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably. Trastuzumab is therefore used to treat HER2 positive (HER2+) breast cancers [1].

The EC approval follows a positive opinion issued on 15 September 2023 by the CHMP of the EMA [2].

The positive CHMP opinion was based on the results from Phase I and Phase III trials. This included an 807-patient Phase III trial (NCT03433313) where subjects either received the biosimilar or Herceptin in combination with the chemotherapy drug, paclitaxel. The study demonstrated that the biosimilar was non-inferior to the reference biologic.

Sandoz is responsible for the worldwide commercialisation of EirGenix’s Herceptin biosimilar, excluding Taiwan, China, Russia, and some Asian countries. Meanwhile, EirGenix retains the rights for development, commercialisation, and manufacturing of the biosimilar in countries not covered by Sandoz.

Europe has now approved seven trastuzumab biosimilars, including Herwenda. They are Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera and Zercepac.

Related articles
Applications for adalimumab and trastuzumab biosimilars submitted to FDA

Sandoz and EirGenix make deal for trastuzumab biosimilar

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Consulta pública para la modificación de la regulación de biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Consulta pública para la modificación de la regulación de biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jan 23]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-trastuzumab
2. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of trastuzumab biosimilar Herwenda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jan 23]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-trastuzumab-biosimilar-herwenda

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
IBD 1
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010